首页> 美国卫生研究院文献>Toxicological Research >In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile
【2h】

In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile

机译:乳酸菌对艰难梭菌的体外抗菌活性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clostridium difficile infection (CDI) has become a significant threat to public health. Although broad-spectrum antibiotic therapy is the primary treatment option for CDI, its use has evident limitations. Probiotics have been proved to be effective in the treatment of CDI and are a promising therapeutic option for CDI. In this study, 4 strains of lactic acid bacteria (LAB), namely, Lactobacillus rhamnosus (LR5), Lactococcuslactis (SL3), Bifidobacterium breve (BR3), and Bifidobacterium lactis (BL3) were evaluated for their anti-C. difficile activity. Co-culture incubation of C. difficile (106 and 1010 CFU/ml) with each strain of LAB indicated that SL3 possessed the highest antimicrobial activity over a 24-hr period. The cell-free supernatants of the 4 LAB strains exhibited MIC50 values between 0.424 mg/ml (SL3) and 1.318 (BR3) mg/ml. These results may provide a basis for alternative therapies for the treatment of C. difficile-associated gut disorders.
机译:艰难梭菌感染(CDI)已成为对公共卫生的重大威胁。尽管广谱抗生素治疗是CDI的主要治疗选择,但其使用存在明显局限性。益生菌已被证明可有效治疗CDI,并且是CDI的有前途的治疗选择。在这项研究中,评估了乳酸杆菌(LR5),乳酸乳球菌(SL3),短双歧杆菌(BR3)和乳酸双歧杆菌(BL3)等4种乳酸菌(LAB)。艰难的活动。艰难梭菌(10 6 和10 10 CFU / ml)与每株LAB的共培养表明SL3在24小时内具有最高的抗菌活性期。 4个LAB菌株的无细胞上清液的MIC50值在0.424 mg / ml(SL3)和1.318(BR3)mg / ml之间。这些结果可为治疗艰难梭菌相关肠道疾病的替代疗法提供基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号